A randomized, open-label, phase 3 study of ZL-1310, a DLL3 antibody-drug conjugate (ADC), compared to investigator’s choice therapy in participants with relapsed small cell lung cancer (DLLEVATE).
Afshin Dowlati(University Hospitals Seidman Cancer Center), Luis Paz-Ares Rodríguez, Pingkuan Zhang(Melanoma Institute Australia), Melissa L. Johnson(Tennessee Oncology), Santosh Nair, Benjamin Jacobs(Seattle Cancer Care Alliance), Caleb J. Smith, Yan Wu(Sichuan University), Paul A. S. Fishkin(Illinois CancerCare), Renke Zhou(Zhejiang University), Ralph V. Boccia(Center for Cancer and Blood Disorders), Manish R. Patel(Sarah Cannon), Yifan Tu(Mercy Research), Raffaele Califano(The Christie NHS Foundation Trust), Gopal Kunta(Sigma Clermont), Koichi Goto(National Cancer Center Hospital East), Maurice Perol(Centre de Recherche en Cancérologie de Lyon), Jun Zhang(OSF HealthCare), John Hamm(Ontario Institute for Cancer Research)
Cited by 1
Related Papers
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761